Amivantamab/Hyaluronidase

埃万妥单抗/透明质酸酶

Report date: 2026/03/09 17:53:38

Base Information

Drug NameAmivantamab/Hyaluronidase
Drug Alias Nameamivantamab and hyaluronidase-lpuj埃万妥单抗注射液（皮下注射）Amivantamab Injection (Subcutaneous Injection)Amivantamab/Vorhyaluronidase AlfaRybrevant Faspro +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Enzyme > Recombinant enzyme
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsEpidermal growth factor receptor erbB1 antagonistsHyaluronic acid modulators
TargetsHepatocyte growth factor receptorEpidermal growth factor receptor erbB1Hyaluronic acid
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2025/12/17
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsYes AmivantamabHyaluronidase recombinant human
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJanssen Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson KkJanssen-Cilag International NvJanssen Biotech Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A